Human Embryonic Stem Cells Global Market Report 2024

The human embryonic stem cells market size has grown rapidly in recent years. It will grow from $1.13 billion in 2023 to $1.24 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth observed in the historic period can be attributed to several factors, including increased funding and investments in stem cell research, regulatory approvals for research and clinical applications, heightened public awareness about stem cell therapies, the emergence of regenerative medicine as a field, and expanded clinical applications of stem cells in various medical treatments.

The human embryonic stem cells market size is expected to see rapid growth in the next few years. It will grow to $1.83 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The surge in the forecasted period's growth can be linked to various factors, including the rise in cell therapy production facilities, heightened demand for regenerative therapies, increased prevalence of cardiac and malignant diseases, progress in stem cell biology research, and enhanced awareness of the therapeutic potential of stem cells. Notable trends expected during this period encompass progress in regenerative medicine, a heightened emphasis on personalized medicine, expanding applications in drug discovery and toxicology, technological advancements, and the expansion of biobanking.

Government funding for regenerative medicine development is anticipated to drive the growth of the human embryonic stem cells market. Regenerative medicine aims to restore normal bodily function by repairing or replacing damaged tissues or organs. This sector is receiving increased government support due to factors such as the growing prevalence of chronic diseases and advancements in stem cell research. Human embryonic stem cells play a crucial role in regenerative medicine by offering potential therapies for tissue and organ repair. For example, the Canadian government allocated $45 million over three years, starting in 2022-23, to bolster stem cell and regenerative medicine research, indicating a strong commitment to this field.

Major players in the human embryonic stem cell market are expanding their focus to include diverse therapeutic applications, such as pluripotent stem cells for treating Parkinson's disease, in order to gain a competitive advantage. Pluripotent stem cells have the potential to generate dopaminergic neurons, which can help restore motor function by replacing lost dopamine-producing neurons. In October 2023, Bayer AG invested $250 million to establish its first Cell Therapy Manufacturing Facility in California, initially targeting BlueRock Therapeutics' bemdaneprocel derived from pluripotent stem cells for Parkinson's disease treatment. This facility, equipped with fully electric manufacturing capabilities, addresses the industry's need for increased regenerative medicine manufacturing capacity.

In February 2024, Charles River Laboratories International Inc., a US-based pharmaceutical company, partnered with Pluristyx Inc. to enhance its portfolio with high-quality embryonic stem cells (ES) and induced pluripotent stem cells (iPSCs). This collaboration enables Charles River to distribute Pluristyx’s extensive line of ES and iPSC cell lines, including genetically engineered and disease state lines, to support therapeutic development. Pluristyx Inc., a US-based stem cell technology company, specializes in providing human induced pluripotent stem cells (iPSCs).

Major companies operating in the human embryonic stem cells market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KgaA, Astellas Pharma Inc., Lonza Group, PerkinElmer Inc., R&D Systems, LifeCell, Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, CellGenix GmbH, PeproTech Inc., Lineage Cell Therapeutics Inc., BioTime, Asterias Biotherapeutics Inc., ESI BIO, STEMCELL Technologies Inc., TATAA Biocenter, Celgene Corporation.

North America was the largest region in the human embryonic stem cells market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human embryonic stem cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the human embryonic stem cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Human embryonic stem cells (hESCs) are pluripotent cells derived from the inner cell mass of a blastocyst, an early-stage embryo. These cells possess the remarkable capability to differentiate into any cell type in the human body, making them immensely valuable for various research and therapeutic applications. The primary uses of hESCs include developing treatments for diseases and injuries by generating healthy tissue and studying disease progression and treatment in a controlled environment.

The main types of human embryonic stem cells are totipotent stem cells, pluripotent stem cells, and unipotent stem cells. Totipotent stem cells can differentiate into any cell type found in an embryo, including extra-embryonic tissues such as the placenta. The products derived from hESCs find applications in regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing. These applications span across research, clinical trials, and other fields.

The human embryonic stem cells market research report is one of a series of new reports that provides human embryonic stem cells market statistics, including the human embryonic stem cells industry global market size, regional shares, competitors with the human embryonic stem cells market share, detailed human embryonic stem cells market segments, market trends, and opportunities, and any further data you may need to thrive in the human embryonic stem cells industry. These human embryonic stem cells market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human embryonic stem cells market consists of sales of stem cell lines, stem cell media and reagents, and stem cell culture equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.